Q4 2024 Management View CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Cencora, Inc. COR reported first-quarter fiscal 2025 adjusted earnings per share (EPS) of $3.73, which beat the Zacks Consensus Estimate of $3.50 by 6.6%. The bottom line also improved 13.7% year over ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

Lola Young’s ode to finding the balance in yourself, Messy, secures a second week at Number 1 in the UK. The tune became Lola’s first UK chart-topper last week, and continues to impress as ...

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) drug. You inject the drug into your stomach, thigh, or upper arm.

The firm's lead program, MET-097i, is in Phase 2b trial as a 'fully biased GLP ... equivalents to fund the completion of the Phase 2 clinical trials for MET-097i, to advance MET-233i through Phase ...

The transaction involves the sale of approximately 19.7 million shares and equivalent warrants ... At a combined price of $1.27 per share and accompanying warrant, the offering is priced at ...